Press "Enter" to skip to content

FDA approves first anticoagulant (blood thinner) for pediatric patients to treat potentially life-threatening blood clots

The FDA approved Fragmin (dalteparin sodium) injection, for subcutaneous use, to reduce the recurrence of symptomatic venous thromboembolism (VTE) in pediatric patients one month of age and older.

Original source: http://www.fda.gov/news-events/press-announcements/fda-approves-first-anticoagulant-blood-thinner-pediatric-patients-treat-potentially-life-threatening

Also Read:   Medtronic Recalls MiniMed Insulin Pumps for Potential Cybersecurity Risks